Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Itacitinib for the prevention of immune effector cell therapy–associated CRS

Matthew Frigault • 12 Dec 2023
ASH 2023
General Itacitinib

In this video, Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, briefly discusses a Phase II study exploring the use of the JAK1 inhibitor itacitinib as a strategy to prevent immune effector cell (IEC) therapy-associated cytokine release syndrome (CRS; NCT04071366). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy: BMS, Kite, Novartis, Covance
Research Funding: Kite, Novartis, Arcellx

More from Matthew Frigault

0:53
Follow-up from a Phase I study of CART-ddBCMA for the treatment of R/R multiple myeloma
Matthew Frigault • 10 Dec 2023
Prophylaxis and management of CRS & ICANS
Bianca Santomasso et al. • 14 Apr 2023
Rapid CAR manufacture
Caron Jacobson et al. • 14 Apr 2023
0:29
ASCO 2022: ZUMA-2, BCMA-targeting BiTEs & novel CARs in myeloma
Matthew Frigault • 3 Jun 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals